Table 2 Comparison between Myocarditis and Non-Inflammatory Left Ventricular Dysfunction

Age (median, IQR)

66 (11)

72 (38)

0.61

Male (n, %)

20 (61)

11 (73)

0.52

BMI (mean, SD)

28 (5)

25 (5.6)

0.16

Smoker (n, %)

6 (18)

4 (27)

0.71

Dyslipidaemia (n, %)

10 (30)

6 (40)

0.51

HTN (n, %)

14 (42)

1 (7)

0.018

DM (n, %)

3 (9)

1 (7)

1

Previous cardiac disease (n, %)

3 (9)

6 (40)

0.018

Previous treatment with anthracyclines

3 (9)

1 (7)

1

Troponin elevation (n, %)

20 (61)

2 (13)

0.004

Increased BNP (n, %)

27 (81)

11 (73)

0.46

Other Immune toxicity (n, %)

24 (73)

4 (26)

0.004

Echocardiogram

  LVEF (median, IQR)

60 (9)

49 (14.5)

< 0.001

  LVEF < 50

2 (6)

11 (73)

< 0.001

  CMR

n = 33

n = 13

  LVEF (median, IQR)

65 (10)

51 (17)

< 0.001

  Positive LGE (n, %)

24 (73)

5 (38)

0.044

  Positive T2STIR (n, %)

9 (27)

0 (0)

0.004

  RVEF (median, IQR)

63 (13)

49 (8)

< 0.001

  Other Immune toxicity (n, %)

24 (73)

4 (26)

0.003

  Immune Checkpoint inhibitor

  Pembrolizumab (n, %)

7 (21)

8 (53)

0.09

  Ipilimumab + Nivolumab (n, %)

11 (33)

0 (0)

0.01

  Atezolizumab (n, %)

3 (9)

2 (13)

1

  Avelumab (n, %)

1 (3)

1 (6)

0.23

  Ipilimumab (n, %)

2 (6)

1 (6)

0.16

  Nivolumab (n, %)

2 (6)

2 (13)

0.69

  Durvalumab (n, %)

5 (15)

0 (0)

0.16

  Dostarlizumab (n, %)

1 (3)

0 (0)

1

  Spartalizumab (n, %)

1 (3)

0 (0)

1